Abstract: A pharmaceutical composition comprising a salt, preferably a crystalline salt, of an organic acid of low water solubility and a compound of formula (I) is provided. The salts are useful in treating Parkinson's disease. Also provided are methods of treatment using the salts and methods of making crystalline forms of the salts.

Abstract: A sustained-release pharmaceutical composition in a form of a tablet comprises (a) alprazolam in an amount of about 0.1 mg to about 5 mg per tablet, (b) a high viscosity HPMC and (c) a low viscosity HPMC, wherein the total amount of HPMC is about 110 mg to about 135 mg per tablet and the high and low viscosity HPMCs are present in a weight ratio of about 40:60 to about 60:40. The tablet can be a member of a series having different amounts of alprazolam in the range from about 0.1 mg to about 5 mg, members of the series having substantially equal total tablet weight and being substantially bioequivalent. The composition is useful in treatment of CNS conditions and disorders including general anxiety disorder, anxiety associated with depression, panic disorder and panic attacks.

Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.